Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
225Ac-ETN029 · 1 trial · 4 indications
A dose limiting toxicity (DLT) is defined as any adverse event or abnormal laboratory value of CTCAE 5.0 grade 3 or higher that occurs within the DLT evaluation period and that is not primarily related to disease, disease progression, intercurrent illness, or concomitant medications with a few exceptions defined in the study protocol. Other significant toxicities may be considered to be DLTs, even if not Grade 3 or higher.
Incidence and severity of treatment-emergent adverse events and serious adverse events, including changes in laboratory values, vital signs, and electrocardiograms qualifying and reported as AEs
Number of dose modifications (e.g, dose interruptions and reductions) for 225Ac-ETN029
Dose intensity of 225Ac-ETN029 defined as the ratio of actual cumulative dose received and actual duration of exposure
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Patients will receive 225Ac-ETN029, with some patients also receiving 111In-ETN029 |
| Name | Type | Description |
|---|---|---|
| 225Ac-ETN029 | DRUG | Radioligand therapy |
| 111In-ETN029 | DRUG | Radioligand imaging agent |
Inclusion Criteria: * Age ≥ 18 years old * Patients with one of the following indications: * Locally advanced, unresectable, or metastatic SCLC with disease progression following, or intolerance to, at least 1 line of systemic therapy, including platinum-containing chemotherapy, unless patient was ...
225Ac-ETN029 is an investigational small molecule being studied for the treatment of Small Cell Lung Carcinoma. It is currently in Phase 1 clinical development, with an active trial recruiting patients with advanced DLL3-expressing solid tumors, including Small Cell Lung Carcinoma.
225Ac-ETN029 targets DLL3, a protein expressed on the surface of certain tumor cells. The drug is designed to deliver a radioactive payload to DLL3-expressing tumors, potentially enabling targeted treatment of cancers such as Small Cell Lung Carcinoma.
225Ac-ETN029 is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker NVS. The company is conducting a Phase 1 clinical trial to evaluate the drug in patients with advanced DLL3-expressing solid tumors.
225Ac-ETN029 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is currently recruiting participants to assess the safety and tolerability of the drug.
225Ac-ETN029 is being evaluated in a Phase 1 clinical trial with the identifier NCT07006727. This open-label, uncontrolled study is recruiting 116 participants with advanced DLL3-expressing solid tumors, including Small Cell Lung Carcinoma, at sites in the United States, Canada, and South Korea.